Skip to main content

Advertisement

Table 2 Baseline patient and tumor characteristics

From: Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling

  Trastuzumab (n = 33) Lapatinib (n = 34) Trastuzumab + Lapatinib (n = 33) Total (N = 100)
Demographics
Age (years)     
Mean (standard deviation) 51.1 (10.90) 50.8 (8.76) 49.2 (10.47) 50.4 (10.01)
Median (range) 54.0 (21-67) 52.0 (25-67) 50.0 (28-66) 51.5 (21-67)
<65 years, n (%) 31 (94) 32 (94) 30 (91) 93 (93)
≥65 years, n (%) 2 (6) 2 (6) 3 (9) 7 (7)
Menopausal status, n (%)     
Postmenopausal 19 (58) 19 (56) 16 (48) 54 (54)
Sterile 5 (15) 5 (15) 6 (18) 16 (16)
Potential to bear children 9 (27) 10 (29) 11 (33) 30 (30)
Race, n (%)     
African American 8 (24) 1 (3) 2 (6) 11 (11)
White/Caucasian 25 (76) 27 (79) 29 (88) 81 (81)
Other 0 6 (18) 2 (6) 8 (8)
Disease characteristics     
Histology, n (%)     
Adenocarcinoma 3 (9) 6 (18) 1 (3) 10 (10)
Medullary 0 0 1 (3) 1 (1)
Lobular invasive 0 1 (3) 2 (6) 3 (3)
Infiltrating ductal NOS 26 (79) 23 (68) 22 (67) 71 (71)
Other 4 (12) 4 (12) 7 (21) 15 (15)
Grade, n (%)     
Not assessed 3 (9) 3 (9) 3 (9) 9 (9)
Well differentiated 0 3 (9) 1 (3) 4 (4)
Moderately 10 (30) 7 (21) 12 (36) 29 (29)
Poorly 20 (61) 21 (62) 17 (52) 58 (58)
Hormone receptor status, n (%)     
Positive (ER + and/or PR+) 15 (45) 14 (41) 20 (61) 49 (49)
Negative (ER- and PR-) 18 (55) 20 (59) 13 (39) 51 (51)
HER2-IHC status, n (%)     
0 2 (6) 0 1 (3) 3 (3)
1+ 0 0 1 (3) 1 (1)
2+ 4 (12) 3 (9) 0 7 (7)
3+ 22 (67) 26 (76) 26 (79) 74 (74)
Unknown 5 (15) 5 (15) 5 (15) 5 (15)
HER2-FISH status, n (%)     
Positive 27 (82) 24 (71) 23 (70) 74 (74)
Negative 0 1 (3) 0 1 (1)
Unknown 6 (18) 9 (26) 10 (30) 25 (25)
Tumor size, n (%)     
T2 22 (67) 12 (35) 22 (67) 56 (56)
T3 8 (24) 11 (32) 6 (18) 25 (25)
T4 3 (9) 8 (24) 5 (15) 16 (16)
Tx 0 3 (9) 0 3 (3)
TNM stage: regional nodes, n (%)     
N0 18 (55) 11 (32) 13 (39) 42 (42)
N1 12 (36) 16 (47) 14 (42) 42 (42)
N2 3 (9) 7 (21) 6 (18) 16 (16)
  1. Abbreviations: ER estrogen receptor, FISH fluorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, NOS not otherwise specified, PR progesterone receptor, TNM tumor, node, metastasis.